| Ytd | -43.03% | |
| 1y | -37.37% |
| Open | 4.65 | Prev Close | 4.64 | Low | 4.65 | High | 4.66 | Mkt Cap | 174.04M |
| Vol | 5.16K | Avg Vol | 206.58K | EPS | -0.98 | P/E | -4.73 | Forward P/E | -9.90 |
| Beta | 1.06 | Short Ratio | 11.20 | Inst. Own | 69.84% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 5.06 | 200-d Avg | 6.34 | 1yr Est | 8.00 |
LFCR News
CHASKA, Minn. , July 15, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecor
Barrington Research analyst Michael Petusky maintains Lifecore Biomedical (NASDAQ:LFCR) with a Ou
-- Agreement Calls for Tech Transfer in Preparation for Potential Commercial Manufacturing of Inject
Lifecore Biomedical (NASDAQ:LFCR) affirms FY2026 sales outlook from $120.000 million-$125.000 millio
Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.43) per share which missed the an
Barrington Research analyst Michael Petusky maintains Lifecore Biomedical (NASDAQ:LFCR) with a Ou
Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated injectables contrac
Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.16) per share. This is a 20 perce
Barrington Research analyst Michael Petusky upgrades Lifecore Biomedical (NASDAQ:LFCR) from Marke
Lifecore stock plunges after earnings miss and weak 2026 outlook, with customer losses and delayed g
Lifecore Biomedical (NASDAQ:LFCR) sees FY2026 sales of $120.000 million-$125.000 million vs $129.846
Indomo Developing Fast-Acting, At-Home Treatment for Inflammatory Acne Lesions to be Administered wi
Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract developmen
On Thursday, 241 companies hit new 52-week lows.